SRF shares surge 6.5% on stellar Q4 results. The specialty chemicals company delivered consolidated revenue of ₹4,615 crore, up 7 percent year-on-year, with EBITDA margins expanding 180 basis points to 25 percent, beating analyst expectations of 23 percent. Adjusted PAT grew 20 percent to ₹690 crore in Q4, while full-year FY26 showed adjusted PAT growth of 51 percent. The strong operational performance was led by the Chemicals business, which reported impressive EBIT margins of 32 percent. The board has indefinitely deferred a ₹490 crore BOPP film facility at Indore but significantly revised upward the refrigerants project capex in Odisha from ₹1,100 crore to ₹2,285 crore, targeting completion by February 2028. Motilal Oswal maintained a Buy rating on the stock, noting that operating performance beat estimates across segments.
